Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to make allergy testing safer for cancer patients on biologics

NCT ID NCT06971848

Recruiting now Knowledge-focused Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

First seen Apr 09, 2026 · Last updated Jun 21, 2026 · Updated 13 times

Summary

This study is testing how to safely perform skin allergy tests in people receiving biotherapies for cancers and blood disorders. Researchers will find the highest concentration of each biotherapy that does not cause a skin reaction in 9 out of 10 patients. The goal is to establish standard guidelines for diagnosing allergic reactions to these drugs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU Angers

    RECRUITING

    Angers, 49933, France

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia bronchogenic carcinoma cholangiocarcinoma colorectal neoplasm esophageal squamous cell carcinoma follicular lymphoma heart cancer hepatocellular carcinoma Immunoglobulin Light-chain Amyloidosis Mesothelioma, Malignant plasma cell neoplasm skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AL AMYLOIDOSIS AL AMYLOIDOSIS BRONCHIAL CARCINOMA CHOLANGIOCARCINOMA CHRONIC LYMPHOCYTIC LEUKEMIA COLORECTAL ADENOCARCINOMA COLORECTAL ADENOCARCINOMA COLORECTAL CANCER ESOPHAGEAL SQUAMOUS CELL CARCINOMA FOLLICULAR LYMPHOMA HEART CANCER HEPATOCARCINOMA HEPATOCARCINOMA HODGKIN'S LYMPHOMA LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK MELANOMA NEOPLASMS MYELOMA PLEURAL MESOTHELIOMA SMALL CELL BRONCHIAL CARCINOMAS